PharmExec Direct eNewsletter

PharmExec Direct:
Having trouble viewing this e-mail? Click here.

You are subscribed to %%list.name%% as %%emailaddr%%.
Click here to unsubscribe or edit your member profile

PharmExec Direct | From the editors of Pharmaceutical Executive

August 12, 2010 | ISSUE NUMBER 161 VOL 8

R&D
Amgen Head and Neck Study: A Disappointment
Head-and-neck cancer treatment trial flops in Phase 3 trials causing Amgen stock to drop. The first-line therapy failed first and secondary goals compared with chemotherapy alone.

Advertisement:
Capgemini
Are You Really Closing the Loop?
There is a considerable advantage to being one of the first companies in pharma to successfully close the loop and pave the way to a new commercial model that puts the customer first. However, implementing comprehensive, closed-loop marketing has proven difficult for many in our industry. Capgemini Consulting examines the functional implications for implementing closed-loop marketing across the commercial organization and the hurdles to overcome to fully close the loop. Click here

Study
Alzheimer’s Test Offers Early Diagnosis
A new spinal fluid test supposedly can determine whether a patient has early-stage Alzheimer’s. Now it’s up to the pharma industry to create treatments to stop the disease in its tracks.

Marketing
Novartis Hits Regulatory Snag with Facebook Widget
Just because a link isn’t on your Web site, doesn’t mean it’s not subject to FDA scrutiny. Novartis found out the hard way with a regulatory letter for a shady Facebook widget.

New & Noteworthy
In Defense of the Battered Sales Rep
Why pharma sales representatives are still the best marketers and how to make them better.

// Bionovo added James H. Pickar, former executive at Wyeth, to medical advisory board. // NeoGenomics appointed Grant Carlson vice president of business development and announced that Mark W. Smits will join the company as vice president of sales and marketing. // OncoGenex named David V. Smith to its board of directors. // OXIS International appointed John Repine to its scientific advisory board. // Generex Oncology named Craig Eagle to its scientific advisory board.

Advertisement:
International Diabetes Summit
Date: 5th - 6th October 2010
Venue: Dubai, UAE

"The human and economic costs of this epidemic are enormous, diabetes increases the risk for heart disease and other health problems, and therefore it is important to give this disease more attention."

To read more kindly visit
Request Brochure

For more information kindly contact Lucia Kasanicka at +9181.0580.5411 or lucia.kasanicka@fleminggulf.com

Sep 9–10 Clinical Trials in Latin America
Lima, Peru

Sep 29–30 6th Annual Bio/Pharmaceutical and Medical Device Product Recalls Summit
Washington, DC

Dec 8—9 CMAC 2010 - Commercialization and Market Access Congress
Orlando, FL

A year and a half into President Obama's tenure, how do you view the effectiveness of the "new" FDA?

Building the Right Incentives

Will Sanofi Bag Genzyme?

Merck: Emerging Markets to Comprise 25 Percent of Global Revenues

The Unintended Consequences of Medical Tourism


	Follow Pharm Exec on Twitter
	Follow Pharm Exec on Facebook

You are subscribed to %%list.name%% as %%emailaddr%%. Click here to unsubscribe or edit your member profile.
To ensure delivery to your Inbox, please add us to your address book. If you need help doing this, click here.

Advanstar Communications provides certain customer contact data (such as customers' names, addresses, phone numbers and e-mail addresses) to third parties who wish to promote relevant products, services and other opportunities which may be of interest to you. If you do not want Advanstar Communications to make your contact information available to third parties for marketing purposes, simply call (toll free) 1-866-529-2922 at any time, or fax us at 1-218-740-6417. Outside the U.S., please phone 1-218-740-6395. Contact us by mail at Advanstar Communications Inc., 131 West First St., Duluth, MN 55802-2065, USA.